Shanghai Pharma(601607) 证券之星·2025-03-27 13:43Core Viewpoint - Shanghai Pharmaceuticals plans to issue debt financing products to expand financing channels, optimize debt structure, and control financial costs while meeting funding needs flexibly [1][2]. Issuance Plan - The company intends to issue various short-term and medium to long-term debt financing products with a total amount not exceeding RMB 15 billion [1][2]. - The types of financing products include but are not limited to short-term financing bonds, ultra-short-term financing bonds, short-term corporate bonds, medium-term notes, medium to long-term corporate bonds, perpetual bonds, quasi-perpetual bonds, asset-backed notes, and other short and medium to long-term debt financing products [1][2]. Fund Utilization - The funds raised from the issuance will be used to supplement the operating capital of the company and its subsidiaries, as well as to repay debts [2]. Financing Terms - The financing term for the short-term debt financing products will not exceed 1 year, while the term for medium to long-term products will be determined based on the company's funding needs and market conditions [2]. Approval and Authorization - The resolution for the issuance must be approved by the company's shareholders' meeting and will be valid for 12 months from the date of approval [2][4]. - The board of directors is authorized to handle specific matters related to the issuance of debt financing products, including determining the issuance plan, negotiating with underwriters, and deciding on the timing and amount of issuance [2][3]. Regulatory Compliance - The issuance plan and authorization matters are subject to approval by the shareholders' meeting and must be reported to relevant regulatory authorities for approval before implementation [4].